It’s Beginning to Look a lot Like Christmas

How can I tell? Because my mailbox (both snail mail and online) are full of donation requests from tons of charities I like. While I was sifting through my options, I was pleasantly surprised to see that The Leukemia & Lymphoma Society (LLS) has received a research challenge grant.

An anonymous friend of LLS will match $100,000 in donations made by December 31st to support an important research focus - to reduce the long-term and late effects of some of today's intensive treatments.

Cure rates for many blood cancer patients have improved dramatically in past decades. But harsh treatments that save lives can come with a cost. Too many cancer survivors experience long-term negative effects from their treatments. Some are chronic conditions that affect quality of life. Others, which might occur years later, can be life threatening.
What patients need now is for current therapies to be made less harmful without sacrificing their effectiveness. This matching challenge will help accomplish that.

Please take advantage of this challenge and double the impact of your gift by December 31st. Your donation of $25 will become $50; your gift of $50 will become $100. Whatever you give will go twice as far. Don't miss this chance to make a gift.
For more information, go to: www.LLS.org

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap